How Do You Know When You’re Ready to Submit an IND? Part 2

Preparing for an effective meeting with the FDA

‍

This is a continuation of our previous blog post, which you can read here.

‍

1. Do You Need a Pre-IND Meeting?

Determining whether a pre-IND meeting is necessary depends on the complexity and novelty of your program, as well as your internal resources and familiarity with FDA processes.

Considering the Complexity of Your Program

• Novel Technologies or Mechanisms: If your therapy involves cutting-edge platforms—such as gene editing, RNA-based therapeutics, cell therapies, or highly specialized small molecules—the regulatory path may be less defined. Early FDA engagement is critical to ensure you are meeting requirements for these emerging modalities.

• Combination Products: When you’re developing a product that integrates a drug, biologic, or device component, additional complexities arise regarding regulatory oversight, manufacturing controls, and clinical study design. A pre-IND meeting can help you navigate these interplays effectively.

Evaluating Internal Expertise and Resources

• In-House Regulatory Knowledge: Companies with limited regulatory experience often find that a pre-IND meeting clarifies expectations and helps them avoid common pitfalls.

• Program Uncertainties: If you’re uncertain about the completeness of your nonclinical package, your manufacturing scalability, or your clinical trial design, consider a pre-IND meeting as an opportunity to reduce risk and strengthen your submission.

In some straightforward cases—where the product type is highly precedented, the nonclinical data is standard, and the manufacturing process is well understood—a pre-IND meeting might be optional. However, most emerging biotech companies can glean significant value from direct dialogue with the FDA, making a pre-IND meeting a wise investment in the long run.

2. Preparing for an Effective Pre-IND Meeting

Preparation is key to making the most of a pre-IND meeting. The FDA will carefully review the briefing package you submit and will expect you to be prepared for clarifications or follow-up questions. Below are strategies to help you maximize your outcomes.

Writing Effective Questions

Crafting clear and strategic questions is the cornerstone of a successful pre-IND meeting. You want to probe the FDA’s thinking on critical elements of your plan:

1. Be Specific:
   Don’t ask broad, unfocused questions like “Is our toxicology package sufficient?” Instead, frame your question around specific studies or endpoints, referencing your data or the relevant sections of your briefing document. For instance: “Based on the repeat-dose toxicology data provided in Section 3.2, does the Agency agree that no additional reproductive toxicity studies are required prior to initiating our proposed Phase I trial?”

2. Prioritize:
   List your questions in descending order of importance. Focus first on questions related to safety, then critical CMC concerns, and finally clinical design or labeling strategies. By tackling the most significant issues first, you ensure they receive the Agency’s attention in case discussion time is limited.

3. Propose a Position:
   Offer the FDA a clear plan or stance: “We believe our standard rodent carcinogenicity studies may be deferred until after Phase II, based on [X]. Does the Agency concur?” This approach invites an actionable response and increases the likelihood of a definitive answer.

Strategies for Negotiating with the FDA

Negotiations with the FDA are less adversarial and more collaborative than many assume. Still, you need a strategy:

1. Know Your “Must-Haves”:
   Identify which aspects of your plan are critical to your program’s viability—perhaps it’s the number of manufacturing runs you can feasibly perform or a particular safety endpoint that must be tested in animals. Communicate these clearly so the FDA understands your constraints.

2. Offer Alternative Approaches:
   If the FDA requests a study or approach that poses a major hurdle for your program, be prepared with alternative methods or study designs. For instance, you might propose a bridging strategy using a different animal model or a different analytical method. Having a backup plan demonstrates your willingness to compromise and fosters a more solution-oriented discussion.

3. Stay Flexible and Collaborative:
   Approach negotiations with an open mind. The Agency’s feedback is often designed to ensure patient safety and to strengthen your application. Being receptive and showing genuine interest in their perspective can lead to a more productive outcome.

Thinking About Questions and Strategies

When formulating your questions, keep in mind not only immediate Phase I concerns but also how decisions made now could affect your long-term clinical plan. For example, if you anticipate needing a pediatric program down the line or plan to seek Accelerated Approval, consider asking early-phase questions that align with these eventual goals. If you plan to use a biomarker for patient stratification in Phase II or III, see if you can obtain feedback now on its acceptability.

Likewise, consider whether you need to request advice on unique endpoints, non-traditional trial designs, or advanced analytics. By introducing these ideas early, you can gauge FDA openness and plan future studies more effectively.

Preparing for a Live Meeting

When it comes time for the actual meeting—whether it’s face-to-face, teleconference, or virtual via a platform like Zoom—advance planning can significantly enhance your effectiveness:

1. Rehearse Thoroughly:
   Conduct internal “mock” sessions where each participant presents their designated topics. This exercise familiarizes your team with the flow, identifies any areas needing clarity, and ensures everyone stays on script.

2. Coordinate Roles:
   Assign specific roles: Who will be the primary spokesperson? Who will handle safety questions, CMC questions, or clinical design details? Having clearly defined responsibilities prevents confusion and ensures a smooth meeting.

3. Bring the Right Experts:
   While you don’t want to overwhelm the FDA with too many people, do ensure you have key domain experts—such as your lead toxicologist or CMC specialist—available to answer in-depth questions.

4. Prepare Materials and Logistics:
   Have any supporting documents, slide decks, or data summaries ready to share if the FDA requests more information. Make sure the meeting platform is tested and that everyone knows the meeting protocol, especially if you’re using a virtual format.

By approaching the pre-IND meeting with a combination of detailed preparation, strategic thinking, and open-minded communication, you not only make the most of the FDA’s feedback but also build a positive relationship that can carry you through the entire drug development process.

3. Moving Forward with Confidence

Filing your IND is a significant milestone, moving your program from the lab to the clinic. It comes with a mix of excitement and responsibility to ensure patient safety and build a solid foundation for clinical efficacy.

Streamlined Development and Reduced Risk:
When you have a comprehensive IND package that addresses all key regulatory requirements—backed by feedback from a productive pre-IND meeting—you significantly reduce the risk of facing a clinical hold. Moreover, you set up a clear roadmap that helps you anticipate and circumvent common pitfalls in early clinical development. By getting the FDA’s early buy-in on your study design and safety assessments, you’re less likely to need significant protocol amendments later, thus saving both time and money.

‍

Leveraging Expert Support:

Despite the thorough planning described above, the IND process can still be challenging. This is where experienced Regulatory Writing and Consulting partners add considerable value. By collaborating with professionals who understand the nuances of FDA expectations, you can refine your briefing packages, sharpen your questions, and facilitate smoother FDA interactions. They can also help you interpret post-meeting feedback to ensure your IND submission is as complete and compelling as possible.

Ultimately, a carefully orchestrated pre-IND strategy—complete with all required data, well-framed questions, and a collaborative approach to negotiations—empowers you to move forward with confidence. You’ll be better positioned to make informed decisions, use resources efficiently, and maintain a strong partnership with regulatory authorities as you advance your innovative therapy toward the patients who need it most.

‍

Ready to take the next step? Our Regulatory Writing and Consulting team is here to support you in assembling and polishing your IND package, preparing an effective pre-IND meeting strategy, and guiding you through the regulatory landscape. Reach out today to discover how we can help you navigate your path to the clinic—and beyond.

‍